The Trump administration is weighing tariffs of up to 200% on imported medicines under national security provisions. Analysts warn even a 25% tariff could raise US drug costs by 10-14%. Experts caution reshoring production will be costly, while legal hurdles and industry pushback add uncertainty. India's $25 billion pharma exports face potential risks.